GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Microba Life Sciences Ltd (ASX:MAP) » Definitions » Common Stock

Microba Life Sciences (ASX:MAP) Common Stock : A$102.88 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Microba Life Sciences Common Stock?

Microba Life Sciences's quarterly common stock increased from Jun. 2023 (A$80.37 Mil) to Dec. 2023 (A$102.81 Mil) and increased from Dec. 2023 (A$102.81 Mil) to Jun. 2024 (A$102.88 Mil).

Microba Life Sciences's annual common stock increased from Jun. 2022 (A$62.88 Mil) to Jun. 2023 (A$80.37 Mil) and increased from Jun. 2023 (A$80.37 Mil) to Jun. 2024 (A$102.88 Mil).


Microba Life Sciences Common Stock Historical Data

The historical data trend for Microba Life Sciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Microba Life Sciences Common Stock Chart

Microba Life Sciences Annual Data
Trend Jun22 Jun23 Jun24
Common Stock
62.88 80.37 102.88

Microba Life Sciences Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial 62.88 80.12 80.37 102.81 102.88

Microba Life Sciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Microba Life Sciences Business Description

Traded in Other Exchanges
N/A
Address
324 Queen Street, Level 10, Brisbane, QLD, AUS, 4000
Microba Life Sciences Ltd is a commercial-stage company with technology for measuring the human gut microbiome and engages in providing gut microbiome testing services globally to consumers, clinicians, and researchers. It is also involved in developing new pathology services, therapeutics, and diagnostics based on the human gut microbiome. The company's operating segments are; Testing Services and Supplements which derives key revenue, and Research and Development. Geographically, the company derives maximum revenue from Australia and the rest from Europe, New Zealand, the United States, Asia, and other regions.

Microba Life Sciences Headlines

No Headlines